Clinical trial

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

NCT05366478

Study summary

ClinicalTrials.gov

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Autologous tumor infiltrating lymphocytes (TILs) Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-05-30

PhasePHASE1

Conditions

Melanomaverified · MONDO: melanoma

Non Small Cell Lung Cancercandidate · MONDO: non-small cell lung carcinoma

Cervical Carcinomaverified · MONDO: cervical carcinoma

Interventions

Autologous tumor infiltrating lymphocytes (TILs)DRUG

Sponsors & collaborators

Suzhou BlueHorse Therapeutics Co., Ltd.lead sponsor

Mapped research locations

TianjinChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05366478 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.